Form 4: UTHR COO Benkowitz Sells Shares via Pre-Planned Trading Plan

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 22,500 shares after exercising stock options, alongside an additional disposal of 2,648 shares.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), engaged in transactions involving the exercise of stock options and subsequent sale of common stock.
• These transactions were conducted under a Rule 10b5-1 trading plan established on June 3, 2025.
• On September 2, 2025, 14,625 stock options were exercised at a price of $135.42 per share. The resulting 14,625 shares were then sold at weighted average prices ranging from $405.5949 to $419.3514.
• On September 1, 2025, 7,875 stock options were exercised at a price of $146.03 per share. The resulting 7,875 shares were then sold on September 2, 2025, at weighted average prices ranging from $407.2642 to $419.63.
• An additional 2,648 shares of common stock were disposed of, without a specified transaction date or price in the filing.
• Following these transactions, the beneficial ownership of common stock in the two trusts involved is 0.00 shares for each.
• Benkowitz retains 172,875 stock options in one trust and 55,125 stock options in another trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While insider selling occurred, it was pre-planned under a Rule 10b5-1 plan, which mitigates negative interpretations. The sales represent a realization of significant gains from previously granted stock options.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, negative information.
• The sales were made at significantly higher prices (ranging from $405.5949 to $419.63) compared to the option exercise prices ($135.42 and $146.03), demonstrating substantial gains for the insider.

Negatives

• Insider selling, even if pre-planned, can sometimes be interpreted by the market as a signal of limited upside potential or a desire for diversification away from the company's stock.
• A significant number of shares (22,500 from option exercises plus 2,648 additional shares) were disposed of.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider selling as a signal, though the pre-planned nature under a 10b5-1 plan generally mitigates negative interpretations.
• The transactions demonstrate that the company's stock has performed well enough to allow the COO to realize substantial gains from his options.

Key Dates

Recommendation

The transactions are routine, pre-planned insider sales under a Rule 10b5-1 plan, primarily for personal liquidity and diversification, not a reflection of a change in the company's fundamental prospects. The significant profits realized by the COO from these option exercises indicate strong past stock performance. These disclosures alone do not provide new information to alter an existing investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Common Stock Sale, Officer Transaction, Biotechnology, Pharmaceuticals